<SEC-DOCUMENT>0001193125-12-186248.txt : 20120426
<SEC-HEADER>0001193125-12-186248.hdr.sgml : 20120426
<ACCEPTANCE-DATETIME>20120426164410
ACCESSION NUMBER:		0001193125-12-186248
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120426
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120426
DATE AS OF CHANGE:		20120426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPLIGEN CORP
		CENTRAL INDEX KEY:			0000730272
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				042729386
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14656
		FILM NUMBER:		12784185

	BUSINESS ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		7814499560

	MAIL ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d341688d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): April&nbsp;26, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>REPLIGEN CORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-14656</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-2729386</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>02453</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (781)&nbsp;250-0111 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report.)
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;26, 2012,
Repligen Corporation issued a press release. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
Exhibits </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1 Press Release by Repligen Corporation, dated April&nbsp;26, 2012. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">SIGNATURES </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPLIGEN CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: April&nbsp;26, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ William J. Kelly</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">William J. Kelly</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT INDEX </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:25pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release by Repligen Corporation, dated April 26, 2012.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d341688dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR>
<TD VALIGN="top" ROWSPAN="4">


<IMG SRC="g341688ex99_1-pg001.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 Seyon Street</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building #1, Suite 100</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Waltham, Massachusetts 02453</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telephone: 781-250-0111</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR IMMEDIATE RELEASE</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telefax: 781-250-0115</FONT></TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CONTACT: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Walter C. Herlihy </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">President&nbsp;&amp; CEO </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">781-419-1900 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Repligen Provides Regulatory Update for RG1068 New Drug Application; </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FDA Cancels Advisory Committee Meeting </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>WALTHAM, MA &#150; April&nbsp;26, 2012</B> &#150; Repligen Corporation (NASDAQ:RGEN) announced today that midday yesterday, the FDA notified the Company that the FDA Advisory Committee meeting
previously scheduled for May&nbsp;31 to review RG1068 for pancreatic imaging has been cancelled by the FDA. The Company expects to receive a Complete Response letter on the previously announced June&nbsp;21 PDUFA date requesting additional clinical
trial data to support the New Drug Application (NDA). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;While we are disappointed in this result, we continue to believe that RG1068 is a
safe and effective agent for imaging of the pancreatic ducts, and that it has the potential to meet a significant unmet patient need,&#148; stated Walter C. Herlihy, President and Chief Executive Officer of Repligen. &#147;We intend to continue our
dialogue with the FDA to assess a potential path forward for RG1068.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">RG1068 is a synthetic version of human secretin which was
evaluated in a Phase 3 study to improve detection of pancreatic duct abnormalities in combination with MRI in patients with pancreatitis. On December&nbsp;21, 2011 we filed a NDA, and on February&nbsp;21, 2012, the FDA accepted the filing of our NDA
and granted it priority review based on its prior Orphan Drug and Fast Track designations. Under the Prescription Drug User Fee Act (PDUFA), the FDA&#146;s goal for completing review of the NDA is June&nbsp;21, 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;5, 2012 we submitted an MAA to the EMA, which has been successfully validated for full review by the EMA&#146;s Committee for Medicinal
Products for Human Use. The U.S. and EU marketing applications are based on positive outcomes from a re-read of our Phase 3 clinical study, supporting the use of RG1068 in combination with MRI to improve detection of pancreatic duct abnormalities in
patients with known or suspected pancreatitis. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Repligen Corporation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Repligen Corporation is a leading supplier of critical biologic products used to manufacture biologic drugs. Repligen also applies its expertise in biologic product development to RG1068 (SecreFlo&#153;),
a synthetic hormone being developed as a novel imaging agent for the diagnosis of a variety of pancreatic diseases. In addition, the Company has two central nervous system (CNS) rare disease programs in Phase 1 clinical trials. Repligen&#146;s
corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested at <U>www.repligen.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>- more - </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repligen Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Committee meeting, April 26, 2012 </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Page 2 of 2 </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This press release
contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Investors are
cautioned that statements in this press release which are not strictly historical statements, including, without limitation</I>, <I>express or implied statements regarding FDA approval of our NDA for SecreFlo</I>&#153;<I>, EMA approval of our MAA
for SecreFlo</I>&#153;,<I> future financial performance and position, plans and objectives for future operations, plans and objectives for product development, and product sales and other statements identified by words like &#147;believe,&#148;
&#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seek,&#148; or &#147;could&#148; and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our ability to obtain FDA approval for our NDA, including the design, timing, cost and similar
uncertainties related to additional clinical studies that FDA may require for approval; whether EMA will require additional clinical studies before approving our MAA and similar uncertainties regarding such additional clinical studies; our ability
to develop and commercialize products and the market acceptance of our products; reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; our ability to compete with
larger, better financed bioprocessing, pharmaceutical and biotechnology companies; the success of our clinical trials; new approaches to the treatment of our targeted diseases; our compliance with all Food and Drug Administration and EMEA
regulations; our ability to obtain, maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales capabilities; our volatile stock price; and other risks
detailed in Repligen&#146;s annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from
those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management&#146;s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its
views or events or circumstances that occur after the date hereof except as required by law. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"># # # </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g341688ex99_1-pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g341688ex99_1-pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`(0"6`P$1``(1`0,1`?_$`'(```$%`0$!````````
M``````@`!@<)"@L$!0$!`````````````````````!````8"`0,"!0(#"0``
M`````@,$!08'`0@)`!$*$A,A(A05%E$R,4$74B2U-G:W&#AX$0$`````````
M````````````_]H`#`,!``(1`Q$`/P"U3RVMU[0U(X_:KCE&V=-JFM>\MAX^
MR)997DJ=H=+$D$@<9D,LEN$#XQ+$+LG(4/OV-.?@HT(3"E&0#[A%G&0SG:A<
M8_DL;J:W51M+5/(?-F2N+E8%,GAR"PMV-AH_+OLI+RYLR=8ZM#9'W]$D`YY:
MQ*4WH5F^XD-*'GTY%D(0$_:B_P#R#N"?9*MV>^=R+.D3O*F8BP(H0\W5(=A:
M.LZ.M+N-K>F9V8)\+W<92JB\IEI1J)M<B"E(#4QQ?N%']!U"-4KMSLKK!KKL
M2)B,BX[UH^J[>-C1HC#!1\ZQH.QRTYFP:<$!IX&PUVR2$P00B,"#`LXQW[=!
M&DFY%-`87-/Z<R[=W4N,3P*L:`V(/VP]3-4A2KRS/:$@6M2V6$JT*[!ORX).
M"`S(OA@/?H"];W!`[($3HU+4CDV.21.O;G%O4DK$"]"K*`H2+$2M.,Q.J2*B
M#`C+,`(0!@%C.,YQGOT$9L-\T;*GQVC$8N:J)')6%*Z+GR/,-B1!X?&9$QFA
M(>ECLTM[PH7MR5G.%@"HPXL`$XLXP9D.>@BVO]Z-*K9L(VI:NVYUHL:T"332
M,U[![QK253,P].$8E)":.,DE6NJLY)@L7O`**&(GMGUX#VZ",>4O8A5JAQT;
MH;!-CF<S2*NM>K'5PQT3J1)%*&P7UB416O%"92'YR%()P^M_MB#\V!]NWQ[=
M!F;\.ZQMJ=@X)NKL+LIL7>5T1QJDU95!7B6VK0F<Y9&%R:&=_FUA+FTB4O+B
MD0KC$,ACX##2PA'@KOC.>V>V0=/'=HKO',>;*?[K6YOI0]NZ]$V#L5;[/0%%
M[GR6V5#.TSK\FC%5,[Q4[:F2QANC,-22Y'D8A"RF(6(B0@P(0@]`=G+YS$W9
M35^5QQ@<8\!:[LY);P*0&J%+FF2.L)USBCPA.=$\GEJ988!G/E.8\28\8*<Q
M!:V9F+"XN`#BCDR92`:C\7K8#:!M(L3D9Y<]K+7OMU3E+UZ:L%8$%90AW%C)
MN&N+))8>J+6M+:=G&"Q(6F-EBQCY$Q..W0"#!K6Y#O'5Y+=2-/+_`-J9/N?Q
MZ[ER9NA4`=[$RY*I/!/NDM98.L7,P']XD;U"I!6+],&A6Y($3DL87AF7>HL@
ME:(.$0;SN@'Z0[9ZKQ&:`K>5[+Z_1BQ#%>$`(%(;EKEEF@UV1X+PB!%G*1IG
MP2O)F<!P7@CU]\]NW?H"`QG`L8$'.,XSC&<9QGOC.,_'&<9Q\,XSCH&*NM*L
M6N-/4S<[&@C=#XV,94BE:Z7Q])&F`PO!>3"WI]4.!;6U#!@X'?!YI><>O'ZX
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M:B:*PI$^6?5$*8G7S)!"D;K(#?=`%<B7)"33,)BE92@*U-B.('@\JG06Q)S6
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MEM5M:U,C1*DR@HX(LBR`LT0:4?(.W7F<H\;K2IUG2TTFU=[F+4-7/2@X^D-=
M`I:Q17K.7?)!6"<%(U<PC+8(16`X`'"T(>W;H)#XMPYX\/%$M[8<X(668V/3
M>SEZH5'Q3G?F-F*G*GZ94B.]/K%E:D:(V:7G]#L8Q^O0`SX9-=,55TYR2;VS
M-+D#%#66*UVB=<%`P8F8*[B\GN&U$Y"@6.^/>2*X\8(/[>Y(<Y_ACH##\32!
M.NT$[Y%N7:Z4^'VZ]@[]>:LCCXOQ]29%F+)#1:=@,\>/.P,Q,T*S99&FP@L&
M0A3(H^40#&"^X>@NZY0.7L_C<F]5P5JTEVBVV<+(BK[+5[A0447N[/"$;6[I
MV=N1O[B4QNJ;+F^'_4C+("((RBDWJ%CL8#/05A4SY&5)[?;HZPZ?V=Q5WQ"K
M=M6<M*"NG+8./08EP@;:Y*CE3Q8S4UR^-D2`AH9$D54+#CV_`!&Y;,A"/)A6
M/2'KYU]_K9G^W6O7"UJUL+'-5'Z^68,[V_VH>)<V0LZGJ14I'IPQ#F"3.;NP
MEM$DD47CZU>H+(6HUR_"AJ0$*"BW!2+`1!8/`AXY9VLTQKZ.7Y5Q=W8A;\I9
M=EWK=AF>;&,GY;*J-0RA]C8;$(K%T1*'H(3EC>6Q$E'%"&$O)1F0G!!P\#W(
M!9;+XY.Q%]6[+'*2.FD:+9^#U])GM<I<W5PCM<U;';"K5D-<E@A*5@6EZG!;
M&W8$(7M(DR8@/8)80X`$_'@X,H=NEH9$[MY`I+8]@ZY36T[!L6A=3&:;2.O:
MV>'K*U#!Y=?EKG0E?'Y3,YI)%T&"ULX35I8$#.VX,",T"[!9(13(^)'32OO)
M6@7&_4L2F'_"&]M93[%VBH1/:%AX:!)X_&I_:T6ACA*4LD)G0XB1;M6P-_*3
MJ7,TX!YV"PFX(&`L(!5L2$ODE\MA%"<B!(X6R;H5U7QZ(&`+&\ROM1F5H.L%
M$'&?=(&@<PU8]&F9S\@A*A9_GT'3AE4:K=+&)$KE42B2J,I&-U62%.Y1UH6M
MYS*E0GJ'0"U(H1F$*4HD18_<`,(@B#WQG&<=!R^?%;@9%W\Z2FWX>QD1J&59
M`MF;I(8VQ/A*UL,?FY"FK(]'4Q!8?;3)$']6R"R2L=L!`F[8_AVZ!@<K#93=
M<^3%<+IR,PV02#5R0W]`)%9*!.*5)3GJAY-6,7:HS(6A3$EC;)W!IC*#"89X
M&D_ZH8FM0E*P(X.2LA8IN?8GB`ZVQF)K*'U57[KS:4.I9!\,J&ZMI(HCC##]
M.>8:]R.6SN9(&TE68K"40G;4Q2E:8(S(C`DEAP(0';O7']>-#?&HON;:[:82
M/0!XY`7NL8NLI&<V3*[&L$@F;29(!.?+G26.CFO9G)]HV).:O[*')0FX"X1:
MDL"KZ@`0!WQ6.7?0/0C6O8VB-OK4(H69RBY`7-%I9(8E-'IBG,260.+1(3(A
M7Q".R,\AYC3G%E!P4Z@LK"HMQQ]-DT8#@@`->0^_YCY.7,#1U#Z?1V5$T#`6
MQ/6\1F#VS*D1K-6_Y(!^NS9"8M1^!YBS2<G-(*;T2H12E42WMJ<99;@L^E"!
M/^8W,6IFN#CIT!JQ.8&-T-K^H>6*)(1X/,)_.GIFJBO6@P`,!R-:A8*=R`C'
M;'R+.^,?/T%J?DN.+?HWP`:R:2,)X$2N4N>LFNQR%(+VLK(W1L&#-Y.Y#]`P
MY,+-E5>-?OY^;`S%OQ_=T!8>/'IJ>3X]2*KQC*CTCW6A.S<K<G`XH6,(A7$F
MD=3Q!X48P7DPTK\%CC0JQVP+N6+';].@K>\5[?*G=+8GLOQ4;J2Z-:S;%5KL
MK-)9&VVW7AN@S1)UC@QQF&S.$(Y&_*$+'F5QM]@>%2=.:>`QU0N99B+!X"3<
MA#5EM!RC\?\`IY7+O9EZ[64RP-3:@4*V^.,4YCTPL&6J"4YIY+5"X#&'!SE$
ME<EN2_0#!";)!>18$<845@1@0R"\2ETVIRP^2[;.[5MUA**JCNN.MCZ[5%6,
MZ0*4D@KF`29E9*^IYO=TBXDO*=^FD3MEXE9PB^Y`E3B<-*(:?VA]`W);1>D]
MS^5)O?5'+#'XRY5_9M51A3K>GM2:R.O(2]RM/!Z&Q`RVZ4L\FB81*%$"9WY$
MB),682GN1)R8(1*_:+R!Q<EFI?C(<;U68D#[IE5-X7M)7%F8JEU:JZ_;A<[;
MLU]>G1`WD@3MS3:$C6QIB3$K,G#<5:(1)HPA3)PGJSB2!AX^:%LJW03QOC:A
MI76--I,MW%L.H&1XUM2SIZLA[@<QL%Q;[8L".N\M>U"EP?9$5$ZJRUN7M?W8
M@W(B"O46$(AAJ"X^Z&*U>T;U(U\"EPC5U)KS4\-?"L!"')DI;8:T_ERLS`,8
M#[J^4&K#QY_CD9F<YSG/QZ#(YI?=J.9\[7,AR-NZD*R&4;=NH6@D6?E.<C:F
MQ-=>X5$ZEJU[<<('M@+*8*W7GC$']I3B,6<]C.^0TUT#PV\:^KVQ&=L:-UC9
MX5L,)7-'#-G&6%;\I=LN%B)G)'-'#[=,K!D,?PM?TKRJ`:;A'@80J!X+R#U=
M!9!(6!HE;`^1>0(PN+#)&=S8'MO&:>0!<T/"(]N<D8CTII"HD*I&I&#(RQ@,
M#@7<(L9[9Z"N+47ARXW]#K24W3J5K<EIJREL6=84X2)FM&ZWT#E%7I4W+G%D
M<V.861(HZXHSE[0E4!]](8(D].687D`PXST#RWDXL]#N1U`Q$;>Z^QFSGJ*(
MSVZ*3I,X2"%V+'&U0HRK.:FV=PIV8)(-D$K$(W[>H4'H,'&#,P3@P619`:M3
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MIA&C]DLO`Q8R$5W[Q#\=6T>QC)MG?FMC19&P,</A"ADG[M/;80_0BKA60NAI
M0(LQSQKA9R1H6)\&9),;ADJ19%[X3?6/U!(>Z7&_I9R'M]?M.Y%)([I;*M62
M)Q@:%PFED1%.PKI60T)GY4$%?3&)_<#ER=B2@QE7[_LA+S[?H]9GJ`G:DJBO
M:)J^OZ7J6,(X76-61!@@4!B:!0O5I([$XNVIVAC:25CJK7NBP*)`E`#)RD\]
M0=G&1F&#&(0LA7/O9PF\;7(U)R;!V;UZ;G6U"4*5L%;,#D,BK:PG!N0$B3H$
M<B>(@XMJ68%-Z?."TV7A.O&F*`$LH0"PX#T$+ZK>.;Q$ZC2]ML.!ZM-D\GK(
MK3KV*47C)Y);V6-<D&(U*O:8Q*UZF"HW)*=D)A*L+5]428`(BS`BQWZ"S>NM
M2M=:EO:\MF:\J]GC5Z[)EP\J[;%3N#^L=IV5`FO[-$RE:-S=UK,TE-3;C!?I
M;DR,)_I"([!@PA%@!SWQXG=">2E-'A;=4,T3Z31!$:V1.PV9YD,&L=@:CE(U
M@V9-,H>YLSLX,.%AIAP&Y<)6@+.-,,`2$PP8A!"NEW`YQ;:%3EOM2A-9FD=L
M,QOU#!9EFR246I+(PI]&2\+HD.:NKHS1%T"6(0<+&Q&D68"(0?=](LXR!E[9
M:)ZH;S-E;LNUE1(+?9ZDFI5B0!J=9--V%O9)F2GPD*>CDD/DT=(>QEI>Y>"7
M`*I-Z!C#[?88^X%OT%=4(XF^/JN*NNJF85KNW,5=[$V="[EN=G)GUKJE\YLV
MNYRR65"I6MDZ^=JY4W*H_.HZD<B24*U*D$>6+`RA`--`,+%>@70+H%T"Z#GA
M>87_`-Y=7/\`RPE_WAL7H.@I!O\`),/_`-+1_P#PE)T#IZ!=`N@70+H%T"Z!
*=`N@70+H%T'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
